cell therapy

Therapies made from living cells, such as CAR-T and stem-cell-derived therapies.

Industry · 4 companies · 2 report it as a revenue line

Show
8-K events
Match any selected event
8-K event types
More events

Only filters 8-Ks. Other selected forms stay visible.

Role
  • ASPE Aspen Neuroscience, Inc.

    Sells it“We have developed an integrated, end-to-end autologous iPSC platform designed to generate autologous cell therapies for the treatment of neurodegenerative diseases (our platform).”

    Latest 424B4final IPO prospectusBankruptcy / going concernPre-revenue ·

    Develops patient-derived Parkinson’s cell therapy; $141M all-primary raise backs sasineprocel’s move toward Phase 3

  • BMY Bristol-Myers Squibb

    Sells it 4%, $1.8B a year“Breyanzi (lisocabtagene maraleucel) is a CD19-directed genetically modified autologous CAR-T cell therapy”

    Latest 10-QQ3 FY2026MixedImpairment / charge ·

    Eliquis drove growth as generics eroded Revlimid and Pomalyst; pipeline licensing charges weighed on earnings.

    • Revenue$13.1BYoY +6.9%
    • Net income$2.2BYoY −1.8%
  • CAPR CAPRICOR THERAPEUTICS, INC.

    In development“Capricor is a clinical-stage biotechnology company developing cell- and exosome-based therapies, including Deramiocel for Duchenne muscular dystrophy (DMD).”

    Latest 10-QQ3 FY2026NegativeRestructuring ·

    Deramiocel’s FDA bid narrows to upper-limb impairment after an adverse cardiac efficacy vote; a Nippon Shinyaku dispute complicates launch plans.

    • Revenue$0vs $0 year ago
    • Net income−$42.7MYoY −73.6%
  • GILD Gilead Sciences

    Sells it 4%, $354.0M a quarter“CAR T therapies Yescarta and Tecartus depend on reliable patient-specific cell engineering, conditioning medicines, side-effect treatments, and a complex network of collection centers, vendors, hospitals, and shipping.”

    Latest 10-QQ3 FY2026Impairment / charge ·

    Acquisition charges and the EVOKE-03 write-off drove a YTD loss despite stronger Biktarvy and Yeztugo sales.

    • Revenue$8.3BYoY +6.8%
    • Net income$2.4BYoY −20.4%

Feedback